OncoLab Co., Ltd. has been officially selected for the “Patent-Driven R&D” commercialization support program, led by the Korean government.
This selection signifies that OncoLab’s core technology has been officially recognized for its commercial viability and global scalability from an intellectual property (IP) standpoint.
Through this program, OncoLab expects to achieve the following outcomes:
> Establishing a Patent-Centered IP Protection and Expansion Strategy
Collaborating with professional IP institutions to develop a tailored strategy encompassing FTO (freedom to operate), global patent filing plans, and competitor patent avoidance.
> Strengthening Global Out-Licensing Readiness
Refining U.S. and EU-centered technology roadmaps to enhance partnering opportunities and negotiation leverage with global pharmaceutical companies.
> Expanding Opportunities for Follow-on Government Support and Investment
Increasing the potential to secure additional funding through commercialization vouchers, export vouchers, and other government-linked initiatives.
> Enhancing IP-Based Corporate Value and Brand Positioning
By being recognized as a government-certified company advancing IP-based commercialization, OncoLab strengthens its credibility and visibility among investors and strategic partners.
OncoLab will continue to drive forward the vision of
“Global technology commercialization, starting from patents.”
“Global technology commercialization, starting from patents.”